Company: KROS
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0001104659-25-037982
Chunk: 26

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 26
---
 non-executive officers. In connection with structuring the executive compensation program, our Compensation Committee, together with the Board, considers whether the elements of such program, individually or in the aggregate, encourage our executive management team to take unnecessary risks. • Our Nominating and Corporate Governance Committee manages the Company’s corporate governance practices and monitors the effectiveness of our Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Nominating and Corporate Governance Committee also reviews risks associated with the independence of the Board, potential conflicts of interest and risks relating to management and Board succession planning. It is the responsibility of the chairperson of each committee of the Board to report findings regarding material risk exposures to the Board as quickly as possible. The Board has delegated to the Board Chair the responsibility of coordinating between the Board and management with regard to the determination and implementation of responses to any problematic risk management issues. Meetings of the Board of Directors and Attendance The Board met nine times during 2024. Each Board member attended 75% or more of the aggregate number of meetings of the Board and of the committees on which he or she served held during the portion of the last fiscal year for which he or she was a director or committee member. It is our policy to encourage our directors to attend the Annual Meeting. A majority of our directors attended our 2024 annual meeting of stockholders. 15

TABLE OF CONTENTS

INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS The Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting information for fiscal 2024 for each of the Board committees:

| Name                          | ​ | ​ | Audit | ​ | ​ | Compensation | ​ | ​ | Nominating andCorporateGovernance | ​ |
| Jean-Jacques Bienaimé(1)      | ​ | ​ |     ​ | ​ | ​ |            ​ | ​ | ​ |                                 X | ​ |
| Nima Farzan                   | ​ | ​ |     X | ​ | ​ |            ​ | ​ | ​ |                                 X | ​ |
| Carl L. Gordon, Ph.D., C.F.A. | ​ | ​ |     ​ | ​ | ​ |        X*(2) | ​ | ​ |                                 ​ | ​ |
| Mary Ann Gray, Ph.D.†         | ​ | ​ |    X* | ​ | ​ |            X | ​ | ​ |